Isoxazolopyrimidines as novel F508-CFTR correctors

Gui Jun Yu, Baoxue Yang, A. S. Verkman, Mark J. Kurth

Research output: Contribution to journalArticlepeer-review

11 Scopus citations


Using a cell-based high-throughput screen, we identified isoxazolo[5,4-d]pyrimidines as novel small-molecule correctors of the cystic fibrosis mutant protein F508-CFTR. 22 Isoxazolo[5,4-d]pyrimidine analogues were synthesized and tested. Synthesis of the key intermediate, 5-amino-3- arylisoxazole-4-carboxamide, was accomplished by nitrile oxide cycloaddition to (2-amino-1-cyano-2-oxoethyl)sodium. Formation of 3-arylisoxazolo-[5,4-d] pyrimidin-4(5H)-one and chlorination gave 4-chloro-3-arylisoxazolo[5,4-d] pyrimidine. Finally, functionalization at C-4 of the pyrimidine ring by nucleophilic substitution gave the targeted isoxazolo[5,4-d]pyrimidines. Six of the reported analogues had low micromolar potency for increasing halide transport in F508-CFTR cells.

Original languageEnglish (US)
Pages (from-to)1063-1066
Number of pages4
Issue number7
StatePublished - 2010


  • Corrector
  • Cystic fibrosis
  • F508-CFTR
  • Isoxazolopyrimidine

ASJC Scopus subject areas

  • Organic Chemistry


Dive into the research topics of 'Isoxazolopyrimidines as novel F508-CFTR correctors'. Together they form a unique fingerprint.

Cite this